Swedish medical technology company SciBase Holding AB (STO: SCIB) announced on Thursday that it has partnered with dermatology practice Seraly Dermatology in Pittsburgh, Pennsylvania.
Through this partnership SciBase will continue to expand access to the Nevisense test to patients across the US and further its commitment to the early detection of melanoma, when the disease is almost 100% curable.
Seraly Dermatology will integrate various Nevisense systems into its skin cancer detection workflow.
Medivir partners with Eisai to evaluate fostrox in liver cancer
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
Cytoki Pharma doses first patient with CK-0045 in Phase two proof-of-concept trial
Formosa Pharmaceuticals signs licensing agreement with DÁVI Farmaceutica
Alchemy partners with PatchRx to improve HIV medication adherence
Bexion Pharmaceuticals reports release of first-in-human data from Phase 1 study of BXQ-350
HUTCHMED receives milestone payment from Takeda for FRUZAQLA sales
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
SciBase and Kilabs partner to advance skin cancer diagnostics in Italy
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
UZ Leuven chooses Sectra for enhanced cancer diagnostics
Biond Biologics signs clinical trial collaboration and supply agreement with Merck KGaA
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI